Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.54 |
| ▸ | AR | P10275 | 8/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808846 | 0.99 | CRBN (0.54) | CRBNARDDB1BTKESR1 | |
| SCHEMBL26808203 | 0.98 | CRBN (0.54) | CRBNARDDB1BTKESR1 | |
| SCHEMBL26806633 | 0.93 | CRBN (0.52) | CRBNARDDB1BTK | |
| SCHEMBL25899965 | 0.90 | CRBN (0.63) | CRBNARDDB1BTKESR1 | |
| SCHEMBL23171819 | 0.90 | CRBN (0.63) | CRBNARDDB1BTKESR1 | |
| SCHEMBL24031726 | 0.89 | CRBN (0.54) | CRBNARDDB1BTKESR1 | |
| SCHEMBL26816783 | 0.88 | CRBN (0.46) | CRBNARDDB1BTKEP300 | |
| SCHEMBL24031698 | 0.88 | AR (0.53) | CRBNARDDB1 | |
| SCHEMBL26815881 | 0.88 | CRBN (0.48) | CRBNARDDB1 | |
| SCHEMBL24031374 | 0.88 | CRBN (0.59) | CRBNARDDB1BTKESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2021231927-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | CRBN 3/4885AR 1/4885DDB1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.